Literature DB >> 19415373

High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1.

S Seitz1, C Schnabel, B Busse, H U Schmidt, F T Beil, R E Friedrich, T Schinke, V F Mautner, M Amling.   

Abstract

UNLABELLED: Although it is known that neurofibromatosis 1 (NF1) patients suffer from vitamin D deficiency and display decreased bone mineral density (BMD), a systematic clinical and histomorphometrical analysis is absent. Our data demonstrate that NF1 patients display high bone turnover and accumulation of osteoid and that supplementation of vitamin D has a beneficial effect on their BMD.
INTRODUCTION: Neurofibromatosis 1 results in a wide range of clinical manifestations, including decreased BMD. Although it has been reported that NF1 patients have decreased vitamin D serum levels, the manifestation of the disease at the bone tissue level has rarely been analyzed.
METHODS: Thus, we performed a clinical evaluation of 14 NF1 patients in comparison to age- and sex-matched control individuals. The analysis included dual X-ray absorptiometry osteodensitometry, laboratory parameters, histomorphometric and quantitative backscattered electron imaging (qBEI) analyses of undecalcified bone biopsies.
RESULTS: NF1 patients display significantly lower 25-(OH)-cholecalciferol serum levels and decreased BMD compared to control individuals. Histomorphometric analysis did not only reveal a reduced trabecular bone volume in biopsies from NF1 patients, but also a significantly increased osteoid volume and increased numbers of osteoblasts and osteoclasts. Moreover, qBEI analysis revealed a significant decrease of the calcium content in biopsies from NF1 patients. To address the question whether a normalization of calcium homeostasis improves BMD in NF1 patients, we treated four patients with cholecalciferol for 1 year, which resulted in a significant increase of BMD.
CONCLUSION: Taken together, our data provide the first complete histomorphometric analysis from NF1 patients. Moreover, they suggest that low vitamin D levels significantly contribute to the skeletal defects associated with the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415373     DOI: 10.1007/s00198-009-0933-y

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  33 in total

1.  The mineralization density of iliac crest bone from children with osteogenesis imperfecta.

Authors:  A Boyde; R Travers; F H Glorieux; S J Jones
Journal:  Calcif Tissue Int       Date:  1999-03       Impact factor: 4.333

2.  Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged > or =60 y.

Authors:  Heike A Bischoff-Ferrari; Thomas Dietrich; E John Orav; Frank B Hu; Yuqing Zhang; Elisabeth W Karlson; Bess Dawson-Hughes
Journal:  Am J Clin Nutr       Date:  2004-09       Impact factor: 7.045

3.  The microscopic structure of bone in normal children and patients with osteogenesis imperfecta: a survey using backscattered electron imaging.

Authors:  S J Jones; F H Glorieux; R Travers; A Boyde
Journal:  Calcif Tissue Int       Date:  1999-01       Impact factor: 4.333

4.  Hypercalcemic hyperparathyroidism and hypophosphatemic osteomalacia complicating neurofibromatosis.

Authors:  R S Weinstein; R L Harris
Journal:  Calcif Tissue Int       Date:  1990-06       Impact factor: 4.333

5.  Scanning electron microscopy in bone pathology: review of methods, potential and applications.

Authors:  A Boyde; E Maconnachie; S A Reid; G Delling; G R Mundy
Journal:  Scan Electron Microsc       Date:  1986

6.  A new scanning electron microscopy approach to the quantification of bone mineral distribution: backscattered electron image grey-levels correlated to calcium K alpha-line intensities.

Authors:  P Roschger; H Plenk; K Klaushofer; J Eschberger
Journal:  Scanning Microsc       Date:  1995-03

7.  Bone mineral density in children and adolescents with neurofibromatosis type 1.

Authors:  David A Stevenson; Laurie J Moyer-Mileur; Mary Murray; Hillarie Slater; Xiaoming Sheng; John C Carey; Bukhosi Dube; David H Viskochil
Journal:  J Pediatr       Date:  2007-01       Impact factor: 4.406

Review 8.  Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease.

Authors:  Michael F Holick
Journal:  Am J Clin Nutr       Date:  2004-12       Impact factor: 7.045

9.  NF1 gene expression in mouse fracture healing and in experimental rat pseudarthrosis.

Authors:  Tommi Kuorilehto; Erika Ekholm; Marja Nissinen; Kalevi Hietaniemi; Ari Hiltunen; Pekka Paavolainen; Risto Penttinen; Juha Peltonen
Journal:  J Histochem Cytochem       Date:  2005-11-28       Impact factor: 2.479

Review 10.  Bone mineralization density distribution in health and disease.

Authors:  P Roschger; E P Paschalis; P Fratzl; K Klaushofer
Journal:  Bone       Date:  2007-11-12       Impact factor: 4.398

View more
  24 in total

1.  Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.

Authors:  Weixi Wang; Jeffry S Nyman; Koichiro Ono; David A Stevenson; Xiangli Yang; Florent Elefteriou
Journal:  Hum Mol Genet       Date:  2011-07-14       Impact factor: 6.150

2.  Bone resorption in syndromes of the Ras/MAPK pathway.

Authors:  D A Stevenson; E L Schwarz; J C Carey; D H Viskochil; H Hanson; S Bauer; H-Y Cindy Weng; T Greene; K Reinker; J Swensen; R J Chan; F-C Yang; L Senbanjo; Z Yang; R Mao; M Pasquali
Journal:  Clin Genet       Date:  2011-01-19       Impact factor: 4.438

3.  Pediatric 25-hydroxyvitamin D concentrations in neurofibromatosis type 1.

Authors:  David A Stevenson; David H Viskochil; John C Carey; Xiaoming Sheng; Mary Murray; Laurie Moyer-Mileur; Judd Shelton; William L Roberts; Ashley M Bunker; Heather Hanson; Stephanie Bauer; Jacques L D'Astous
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

4.  Bone Status According to Neurofibromatosis Type 1 Phenotype: A Descriptive Study of 60 Women in France.

Authors:  Maud Jalabert; Salah Ferkal; Jean-Claude Souberbielle; Emilie Sbidian; Arthur Mageau; Florent Eymard; Philippe Le Corvoisier; Laurence Allanore; Xavier Chevalier; Pierre Wolkenstein; Sandra Guignard
Journal:  Calcif Tissue Int       Date:  2021-02-08       Impact factor: 4.333

5.  Decreased bone mineralization in children with Noonan syndrome: another consequence of dysregulated RAS MAPKinase pathway?

Authors:  Kiran S Choudhry; Monica Grover; Alyssa A Tran; E O'Brian Smith; Kenneth J Ellis; Brendan H Lee
Journal:  Mol Genet Metab       Date:  2012-04-11       Impact factor: 4.797

6.  AN ADJUNCTIVE USE OF ASFOTASE ALFA AND ZOLEDRONIC ACID AFTER SPINAL SURGERY IN NEUROFIBROMATOSIS TYPE 1 RELATED DYSTROPHIC SCOLIOSIS.

Authors:  Tasma Harindhanavudhi; Takashi Takahashi; Anna Petryk; David W Polly
Journal:  AACE Clin Case Rep       Date:  2020-08-06

Review 7.  Aberrant Myeloid Differentiation Contributes to the Development of Osteoporosis in Neurofibromatosis Type 1.

Authors:  Steven D Rhodes; Feng-Chun Yang
Journal:  Curr Osteoporos Rep       Date:  2016-02       Impact factor: 5.096

8.  Bone mineral density in children and young adults with neurofibromatosis type 1.

Authors:  Maya B Lodish; Urania Dagalakis; Ninet Sinaii; Ethan Bornstein; Aerang Kim; Kelsey B Lokie; Andrea M Baldwin; James C Reynolds; Eva Dombi; Constantine A Stratakis; Brigitte C Widemann
Journal:  Endocr Relat Cancer       Date:  2012-11-19       Impact factor: 5.678

9.  c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions.

Authors:  Yongzheng He; Steven D Rhodes; Shi Chen; Xiaohua Wu; Jin Yuan; Xianlin Yang; Li Jiang; Xianqi Li; Naoyuki Takahashi; Mingjiang Xu; Khalid S Mohammad; Theresa A Guise; Feng-Chun Yang
Journal:  PLoS One       Date:  2012-11-07       Impact factor: 3.240

10.  Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Douglas R Stewart; Bruce R Korf; Katherine L Nathanson; David A Stevenson; Kaleb Yohay
Journal:  Genet Med       Date:  2018-04-26       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.